NCT03827850: FIND

FGFR Inhibitor in FGFR Dysregulated Cancer

Terminated Phase 2 Last updated 9 June 2023

What this trial tests

Phase 2 trial testing ERDAFITINIB in Lung Cancer in 22 participants. Terminated before completion.

Timeline

25 March 2019

Primary endpoint
30 September 2022

14 October 2022

Quick facts

Lead sponsor	Lung Cancer Group Cologne
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	25 March 2019
Primary completion	30 September 2022
Estimated completion	14 October 2022
Sites	11 locations across Germany

Drugs / interventions tested

• ERDAFITINIB (ERDAFITINIB) — full drug profile →

Conditions studied

• Lung Cancer — all drugs for Lung Cancer →
• NSCLC — all drugs for NSCLC →
• Pulmonary Neoplasm — all drugs for Pulmonary Neoplasm →
• Squamous Cell Lung Cancer — all drugs for Squamous Cell Lung Cancer →

Sponsor

Lung Cancer Group Cologne

Who can join

18 and older, any sex, with Lung Cancer or NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the FIND trial, Non Small Cell Lung Carcinoma (NSCLC) patients with Fibroblast Growth Factor Receptor (FGFR) genetic alteration will be treated with the selective FGFR1-4 inhibitor erdafitinib. Archival samples, fresh frozen tumor samples and blood for circulating tumor DNA (ctDNA) will be collected before treatment. Patients will be treated until disease progression or unacceptable toxicity. In case of progression, fresh frozen tumor biopsies and ctDNA analyses will be performed to assess resistance mechanisms. The primary objective of the trial is to analyze the efficacy of erdafitinib in NSCLC patients with FGFR genetic alterations. NSCLC patient number will be based on a statistical hypothesis aiming at increasing the response rate comparing to chemotherapy/immunotherapy after standard treatment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
   Liu ZL, Chen HH, Zheng LL, Sun LP, et al · · 2023 · cited 808× · PMID 37169756 · DOI 10.1038/s41392-023-01460-1
2. FGFR-TKI resistance in cancer: current status and perspectives.
   Yue S, Li Y, Chen X, Wang J, et al · · 2021 · cited 98× · PMID 33568192 · DOI 10.1186/s13045-021-01040-2
3. FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
   De Luca A, Esposito Abate R, Rachiglio AM, Maiello MR, et al · · 2020 · cited 87× · PMID 32962091 · DOI 10.3390/ijms21186856
4. Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.
   Liu Y, Cao M, Cai Y, Li X, et al · · 2020 · cited 71× · PMID 32154250 · DOI 10.3389/fcell.2020.00095
5. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
   Levine KM, Ding K, Chen L, Oesterreich S. · · 2020 · cited 68× · PMID 32492514 · DOI 10.1016/j.pharmthera.2020.107590
6. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges.
   Chen L, Zhang Y, Yin L, Cai B, et al · · 2021 · cited 50× · PMID 34732230 · DOI 10.1186/s13046-021-02156-6
7. Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.
   Pacini L, Jenks AD, Lima NC, Huang PH. · · 2021 · cited 46× · PMID 34068816 · DOI 10.3390/cells10051154
8. Biological Significance and Targeting of the FGFR Axis in Cancer.
   Chioni AM, Grose RP. · · 2021 · cited 45× · PMID 34830836 · DOI 10.3390/cancers13225681